|
In patients with impaired renal function (creatinine clearance <50 mL/ min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION.) Moderate to severe phototoxicity reactions have been observed in patients exposed to direct sunlight while receiving drugs in this class. Excessive exposure to sunlight should be avoided. However, in clinical trials with levofloxacin, phototoxicity has been observed in less than 0.1% of patients. Therapy should be discontinued if phototoxicity (e. g., a skin eruption) occurs. As with other quinolones, levofloxacin should be used with caution in any patient with a known or suspected CNS disorder that may predis-pose to seizures or lower the seizure threshold (e. g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (e. g., certain drug therapy, renal dysfunction). (See WARNINGS and Drug Interactions.) Text Continues Below
As with other quinolones, disturbances of blood glucose, including symp-tomatic hyper-and hypoglycemia, have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e. g., glyburide/ glibenclamide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, levofloxacin should be discontinued immediately and appropriate therapy should be initiated immediately. (See Drug Interactions and ADVERSE REACTIONS.) Some quinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. During post-marketing surveillance, rare cases of torsades de pointes have been reported in patients taking levofloxacin. These reports generally involved patients with concurrent medical con-ditions or concomitant medications that may have been contributory. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
